Form 4: Apogee CMO Dambkowski Exercises Options, Sells Shares

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, exercised stock options and sold a portion of his common stock holdings under a pre-arranged trading plan, while also correcting a previous reporting error.

Summary

• Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc., engaged in multiple transactions on January 7, 2026.
• He acquired 14,025 shares of common stock by exercising stock options at a price of $22.86 per share.
• Concurrently, he disposed of a total of 18,700 shares of common stock through several sales transactions.
• The sales were executed at weighted average prices ranging from $77.13 to $80.06 per share.
• All sales were conducted under a Rule 10b5-1 trading plan adopted on September 22, 2025.
• The filing also corrected an administrative error from a previous Form 4 filed on October 3, 2025, which had overstated beneficial ownership by 53,910 shares.
• Following these transactions, Dambkowski beneficially owns 212,523 shares of Apogee Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, these sales were pre-planned under a 10b5-1 plan and occurred at significantly higher prices than the option exercise price, indicating a profitable event for the insider. The correction of an administrative error is a minor negative but a necessary procedural step.

Positives

• The Chief Medical Officer exercised stock options, indicating a potential belief in the company's long-term value at the time of option grant.
• Shares were sold at significantly higher prices ($77.13 $80.06) than the option exercise price ($22.86), indicating a profitable transaction for the insider.
• The sales were conducted under a Rule 10b5-1 trading plan, which suggests pre-planned diversification or liquidity rather than a reaction to immediate negative news.

Negatives

• An administrative error in a previous Form 4 led to an overstatement of beneficial ownership by 53,910 shares, which required correction.
• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct stake in the company.

Risks

• The administrative error in a previous filing highlights a potential for inaccuracies in reporting, which could impact investor confidence if not promptly corrected.

Future Outlook

NA

Industry Context

This Form 4 filing details routine insider transactions (option exercise and subsequent sale) for a Chief Medical Officer at a biotechnology company. Such transactions are common for executives managing personal finances and diversifying holdings, especially when stock options vest and become profitable. The use of a Rule 10b5-1 plan is standard practice to mitigate concerns about insider trading.

Related Party Transactions

• The transactions detailed are related party transactions as they involve an officer of the company exercising options and selling shares of the issuer.

Stakeholder Impact

• Shareholders: The correction of the beneficial ownership figure provides more accurate information to shareholders. Insider selling, even under a 10b5-1 plan, might be viewed with mixed sentiment, but the high sale prices reflect a profitable outcome for the insider.
• Employees: No direct impact on employees is indicated, though the Chief Medical Officer's continued service is tied to future option vesting.

Next Steps

• The remaining 139,540 stock options will continue to vest in forty-eight equal monthly installments through December 18, 2027, subject to Carl Dambkowski's continued service to Apogee Therapeutics.

Key Dates

Recommendation

This Form 4 filing primarily details routine insider transactions (option exercise and subsequent sale under a 10b5-1 plan) and a correction of a previous administrative error. While the insider sold shares, it was pre-planned and at a significant profit, which does not necessarily signal a negative outlook for the company. The administrative error is a minor procedural issue. There is no new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation based solely on this filing. Therefore, a 'hold' recommendation is appropriate as this filing does not provide sufficient new information to alter an existing investment thesis.

Keywords

Apogee Therapeutics, APGE, Carl Dambkowski, Chief Medical Officer, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Beneficial Ownership